UAE investment a boost for UK life sciences

24 March 2021

Abu Dhabi’s Mubadala Investment Company is to invest £800 million ($1.1 billion), alongside £200 million from the British government, in UK life sciences as part of a partnership announced on Thursday.

These funds will provide investment in new life science companies around the country. The industry is also expected to benefit from stronger links in the field between the United Arab Emirates (UAE) and UK.

"Access to capital to scale at pace in the UK remains the key constraint in the funding landscape for UK life science companies"This partnership between the UAE and the UK will build on the investment model Mubadala has established in other geographies.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK